1. health and fitness
2. disease
3. cancer

LEADERS IN ONCOLOGIC INTERVENTIONS
ECIO 2015
Sixth European Conference
on Interventional Oncology
April 22-25, 2015
Nice, France
PRELIMINARY
PROGRAMME
www.ecio.org
C RSE
Cardiovascular and Interventional Radiological Society of Europe
LE AD E R S I N O N CO LO G I C
ECIO is now well established as an annual event, and the
interest shown and the feedback received have demonstrated
that the move to an annual format was a wise one. The field of
interventional oncology is growing rapidly, and ECIO offers a
structured space in which practitioners can stay abreast of the
latest developments and learn new techniques.
Oncology is a field that requires inter-disciplinary collaboration.
Patients now benefit from a vast array of specialist knowledge,
but this brings its own challenges, and ECIO is striving to
ensure its educational programme reflects and supports a
A. Adam
C. Ayuso
A.-M. Belli
P. Chevallier
collaborative approach. This includes working with diverse
partner societies on a variety of joint sessions, and we are
delighted that such sessions will again be offered.
The president of the Japanese Society of Interventional
Radiology, which has been strongly focused on interventional
oncology for many years, will be delivering this year’s
Honorary Lecture. Dr. Yasuaki Arai, who has been at the
forefront of the discipline in the Asia-Pacific, will be giving a
speech entitled Beyond the evidence – the true goal of
interventional oncology.
T. de Baère
A. Denys
A. Gangi
J.-F.H. Geschwind
COMMITTEES
Advisory Board
Scientific Programme Committee
Local Host Committee
Andreas Adam (UK)
Thierry de Baère (FR)
Johannes Lammer (AT)
Riccardo Lencioni (IT)
Jan H. Peregrin (CZ)
Jim A. Reekers (NL)
Thierry de Baère (FR), Chairperson
Thomas K. Helmberger (DE),
Deputy Chairperson
Carmen Ayuso (ES)
Anna-Maria Belli (UK)
Patrick Chevallier (FR)
Alban Denys (CH)
Afshin Gangi (FR)
Jean-François H. Geschwind (US)
Patrick Haage (DE)
Robert A. Morgan (UK)
Franco Orsi (IT)
Philippe L. Pereira (DE)
Patrick Chevallier (Nice), Chairperson
Guillaume Baudin (Nice)
Sébastien Bommart (Montpellier)
Pascal Chabrot (Clermont-Ferrand)
Afshin Gangi (Strasbourg)
Jean-Yves Gaubert (Marseille)
Boris Guiu (Montpellier)
Hicham Kobeiter (Créteil)
Sébastien Novellas (Nice)
Frank Pilleul (Lyon)
Hervé Trillaud (Bordeaux)
Vincent Vidal (Marseille)
I NTE RV E NTI O N S
The meeting has grown over the years, and now encompasses
a wide range of session formats, which cater to all styles of
learning. The Video Learning Sessions, whose debut in 2014
was well received, will be featured again this year, addressing
liver, kidney and lung cancer, as well as the important topic of
pain management.
Clinical management is an essential pre-requisite for offering
a robust interventional oncology service. To support interdisciplinary collaborations and negotiations, a number of
Multidisciplinary Tumour Boards will be held, discussing
various liver and lung cancer cases.
Alongside a wide range of technical advances, ECIO 2015 will
cover both established and experimental applications, such as
musculoskeletal tumours, lung metastases, and thyroid,
adrenal and prostate lesions.
The Mediterranean city of Nice offers an excellent location
for the congress. Located within driving distance of Italy,
Switzerland and Spain, the city’s fame as a beauty spot also
translates into a multitude of flight connections.
We look forward to welcoming you to Nice!
On se retrouve à Nice!
P. Haage
T.K. Helmberger J. Lammer
R. Lencioni
R.A. Morgan
F. Orsi
J.H. Peregrin
P.L. Pereira
Content
2
3
4
5
6-7
8-20
22
23
24
Preliminary Faculty
Honorary Lecture
Incentive Programme
6 years of ECIO – 6 reasons to attend
Programme Overview
Scientific Programme
Hands-on Workshops
Registration / CME / Important Addresses
Accommodation / City Map
J.A. Reekers
2
Preliminary Faculty
European Conference on Interventional Oncology
Preliminary Faculty
as per printing date – subject to change
Amoretti N. Nice/FR
Krokidis M. Cambridge/UK
Anderson C. London/UK
Lencioni R. Pisa/IT
Anty R.
Nice/FR
Lewandowski R.J.
Chicago, IL/US
Arai Y.
Tokyo/JP
Littrup P.J.
Detroit, MI/US
Arnold D.
Freiburg/DE
Mahnken A.H.Marburg/DE
Ayuso C.
Barcelona/ES
Majno P.
Geneva/CH
Baek J.H.
Seoul/KR
Malagari K. Athens/GR
Bezzi M.
Rome/IT
Malek N.P. Tübingen/DE
Bilbao J.I.
Pamplona/ES
Manca A.
Candiolo/IT
Bize P.E.
Lausanne/CH
Marquette C. Nice/FR
Breen D.J.
Southampton/UK
McCrone P. London/UK
Callstrom M.R.
Rochester, MN/US
Mindjuk I.
Dachau/DE
Caridi J.G.
New Orleans, LA/US
Miyayama S. Fukui/JP
Carrafiello G. Varese/IT
Monfardini L. Milan/IT
Chevallier P.
Nice/FR
Napoli A.
Rome/IT
Clasen S.R. Tübingen/DE
Narayanan G.
Miami, FL/US
Cornelis F. Bordeaux/FR
Orsi F.
Milan/IT
Crocetti L. Pisa/IT
Palussière J. Bordeaux/FR
de Baère T.
Villejuif/FR
Paradis V.
Clichy/FR
den Brok M.
Nijmegen/NL
Pelage J.-P. Caen/FR
Denys A.
Lausanne/CH
Pereira P.L. Heilbronn/DE
Deschamps F.Villejuif/FR
Ricke J.
Magdeburg/DE
Dupuy D.E.
Providence, RI/US
Rilling W.S.
Milwaukee, WI/US
Duran R.
Lausanne/CH
Ronot M.
Clichy/FR
Faivre S.
Lausanne/CH
Ryan A.G.
Waterford City/IE
François E. Nice/FR
Sabharwal T. London/UK
Gangi A.
Strasbourg/FR
Salem R.
Chicago, IL/US
Garcia-Mónaco R.D. Buenos Aires/AR
Samuels S.L.
Miami, FL/US
Garnon J.
Strasbourg/FR
Sangro B.
Pamplona/ES
Gervais D.
Boston, MA/US
Sofocleous C.T.
New York, NY/US
Geschwind J.-F.H.
Baltimore, MD/US
Sommer C.M. Heidelberg/DE
Gillams A.
London/UK
Suh R.D.
Los Angeles, CA/US
Goldberg N. Jerusalem/IL
Tanaka T.
Kashihara/JP
Guiu B.
Montpellier/FR
Tapping C. Oxford/UK
Helmberger T.K.
Munich/DE
Tsoumakidou G.
Strasbourg/FR
Inaba Y. Nagoya/JP
Wood B.J.
Bethesda, MD/US
Jereczek-Fossa B.
Milan/IT
Woodrum D.A.
Rochester, MN/US
Kelekis A.D. Athens/GR
Yamakado K. Tsu/JP
Kenny L.M. Brisbane/AU
Zech C.J.
Basel/CH
Preliminary Programme
3
ECIO 2015
ECIO 2015 Honorary Lecture
Yasuaki Arai
Yasuaki Arai is Director of, and Chief of the Department of
Diagnostic Radiology at, the National Cancer Center Hospital in
Tokyo. He also currently serves as the President of the Japanese
Society of Interventional Radiology (JSIR).
During his residency in internal medicine, Dr. Arai became
interested in chemotherapy, and pursued the path of becoming a “medical oncologist”, a term that was not yet particularly
well-recognised at the time. He was not satisfied with the
clinical results achieved with systemic chemotherapy, and so
began exploring the possibility of using a different approach.
This ultimately resulted in the invention of an implantable port
system, as well as the development of a technique involving
placing a catheter via the left subclavian artery for hepatic
arterial infusion chemotherapy, a concept first addressed in a
publication in a Japanese medical journal in 1983.
A year later, Dr. Arai shifted direction, focusing on intervention­
al radiology at the Aichi Cancer Center, where he practiced for
20 years. Many younger radiologists have joined this institute over
the years in order to receive training in interventional radiology.
Dr. Arai founded the Japanese Society of Implantable PortAssisted Regional Treatment in 1986, aiming to facilitate the
nationwide sharing of knowledge about interventional radiology
and the role the specific technique could play in treating cancer.
He has led the society, which provides a forum for specialists to
exchange information across departments, ever since. The im­
plantable port system was ultimately introduced in the article
entitled “Management of patients with unresectable metastases
from colorectal and gastric cancer employing an implantable
port system” (Cancer Chemother. Pharmacol. 31:S990102. 1992).
Dr. Arai has pursued the development of new IR devices and
techniques in order to offer better treatment options throughout his entire career. In addition to his work on the implantable
port system and the hepatic arterial chemotherapy technique, in 1992, he collaborated with Toshiba Medical Systems
Corporation to develop the prototype of a diagnostic system,
consisting of a fluoroscopy and a CT scanner, which is currently
well-known as the Angio-CT suite. Furthermore, he has devised
various approaches that apply interventional radiological tech­­
niques for palliative care purposes, including using a trans-jugular
trans-hepatic peritoneovenous shunt for the management of
refractory ascites; embolisation of various tracts and fistula; the
percutaneous creation of bilio-intestinal anastomosis; and the
creation of an extra-anatomic splenoportal for bleeding ectopic
varices. Their application in palliative care stemmed from his
20 years of experience at the Aichi Cancer Center, where he
treated thousands of patients suffering from progressive cancer.
Strengthening interventional radiology’s evidence base has
been another major priority for Dr. Arai during the past 20 years.
In 2002, he set up the Japan Interventional Radiology in Onco­
logy Study Group (JIVROSG) in order to facilitate pursuing evi­
dence on interventional oncology. Twenty-six clinical studies
have been conducted so far, and JIVROSG has published
articles on some of these studies, including one entitled
“Prospective study of transcatheter arterial chemoembolization
for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea” (J Vasc Interv Radiol. 24:
490-500, 2013). JIVROSG has set itself the challenge of conducting randomised trials that compare interventional radiological
procedures to the best treatments available for palliative care.
Yasuaki Arai has been an associate editor for the Journal of
Vascular and Interventional Radiology, the Cardiovascular and
Interventional Radiology Asia-Pacific Journal of Clinical Oncology,
and the International Cancer Conference Journal, and has also
served as reviewer for several journals. He is a member of
several governmental committees in Japan, including
for the Ministry of Health, Labour and Welfare and the
Pharmaceuticals and Medical Devices Agency. Dr. Arai
has been a board member of the Japanese Society of
Inter­ventional Radiology for years, helping to establish and
expand the reach of interventional radiology in Japan. He is
currently its president, and aims to help ensure that interventional radiological procedures become evidence-based,
standard treatments, as well as to further IR’s global scope.
Since 2004, Dr. Arai has served in the Department of Diagnostic
Radiology in the National Cancer Center Japan. Even after
leading the institute as the hospital’s director, he remains
engaged with the outpatient clinic and with IR procedures.
In his spare time, Dr. Arai enjoys mountain climbing and
cooking, activities that reflect his preference for tackling
challenges with both knowledge and the proper technique.
Honorary Lecture
Beyond the evidence – the true goal
of interventional oncology
Thursday, April 23
10:30-11:30
ECIO 2015
Incentive Programme
€100,000 Education Grant
CIRSE supports the “Referring Physician”
programme with €100,000!
The ECIO Incentive Programme allows radiologists
with a full registration for ECIO 2015 in Nice to
invite their referring physician to the conference
free of charge.
The first 100 referring physicians to sign up
will receive free registration and up to
€1,000 travel support.
For further information and
registration please go to
www.ecio.org
6 years of ECIO
6 reasons to attend
1 Video Learning Sessions
4 Multidisciplinary Tumour Boards
This interactive session format made its debut last
year, and due to the hugely positive response
received, it has been decided to extend the sessions
on offer this year, to cover liver interventions, lung and
kidney therapies, and pain management, guiding you
through the procedures step by step.
Much as they do in the hospital setting, these tumour
boards enable participants to actively discuss treatment strategies for specific HCC and lung cancer cases.
Guided by the mixed-specialty panel, the audience
can vote on optimal therapeutic approaches and
discuss the likely outcomes.
2 Best IO Papers
5 Referring Physician Incentive Programme
Interventional oncology is a growing field, and both
new advances and data supporting existing therapies are of the utmost importance. The Best IO Papers
session will round up some of the most interesting
research from the past year, providing you with
a concise overview of current trends.
For many years, the Referring Physician Programme
has been enabling interventionists to bring their nonradiologist colleagues to the meeting, where they can
see the range of therapies on offer, and the evidence
for their use, first-hand. Will you be bringing your
colleague to Nice this year?
3 Joint Session with ESMO
6 Nice la Belle
To both reflect and enhance the multidisciplinary
nature of interventional oncology, joint sessions are
held with other medical societies. These provide
valuable insights into collaborative possibilities. Our
long-time partner, the European Society for Medical
Oncology will join us again for a fascinating session on
Friday.
‘Nice the Beautiful’ is a wonderful destination for a
congress – its picturesque surroundings and mild
climate have resulted in the third busiest airport in
France, many international train connections, and the
second largest hotel capacity in the country. The perfect place for a congress: in hosting ECIO 2015, the city
has plenty to inspire not only impressionists, but also
interventionists!
Wednesday, April 22
Thursday, April 23
30
45
Satellite Symposia
08:00
15
30
45
09:00
15
30
CF 801
Lung metastases
CF 101
Early-stage HCC
45
VL 802
How I do it: liver
p8
10:00
p12
Coffee break
15
p12
Coffee break
30
45
11:00
15
30
CF 201
Intermediate HCC
45
p8
12:00
HL 901
Honorary Lecture
TA-HoW 1
Image-guided
tumour ablation
– MSK
TF 202
Top tips
p8
TA-HoW 3
Image-guided tumour
p12 ablation – liver
p9
PS 902
The best IO papers of 2014 p12
p12
15
30
Lunch break
Lunch break
45
13:00
15
30
45
Satellite Symposia
Satellite Symposia
14:00
15
30
Break
Break
45
15:00
15
30
45
16:00
IS 401
Multidisciplinary
Tumour Board:
HCC
15
TF 402
Ablation: current
status and future
horizons
p9
30
TA-HoW 2
Image-guided
tumour ablation
– lung
p9
IS 1101
Multidisciplinary
Tumour Board:
lung
p9
p13
Coffee break
45
JS 1102
Essence of interventional oncology
Joint session
with JSIR
TA-HoW 4
Image-guided
tumour ablation –
kidney
p13
p13
Coffee break
17:00
15
30
45
18:00
15
p10
30
45
CF 502
Symptomatic cancer
treatment
CF 501
How to follow up patients:
clinical and imaging
CF 1201
Ablation: evidence for
expanding the boundaries
p10
Satellite Symposia
e-voting
Preliminary Programme
p13
Satellite Symposia
19:00
recommended for EBIR preparation
CF 1202
Fundamentals of oncology
p14
Friday, April 24
Saturday, April 25
30
45
08:00
Satellite Symposia
15
30
45
09:00
15
30
JS 1502
Colorectal liver metastases
ECIO invites ESMO
CF 1501
MSK tumours
45
p16
10:00
IS 2101
Management of complications II
Coffee break
15
p20
p16
Coffee break
30
45
11:00
15
30
CF 1602
Intra-arterial therapies:
what is the evidence?
CF 1601
Kidney cancer
45
p16
12:00
VL 2201
How I do it: pain management
p16
p20
15
30
Lunch break
45
13:00
15
30
45
Satellite Symposia
14:00
15
30
Break
45
15:00
15
30
45
16:00
VL 1801
How I do it: lung and kidney
15
CF 1802
Quality pays: clinical
excellence saves money
p17
30
p17
Coffee break
45
17:00
15
30
45
18:00
15
p17
30
45
19:00
JS 1902
Molecular oncology and
translation into the clinic
Joint session with WCIO
IS 1901
Management of
complications I
Satellite Symposia
p18
CF: Clinical Focus Session
HL: Honorary Lecture
HoW: Hands-on Workshop
IS: Interactive Session
JS: Joint Session
PS: Paper Session
TF: Technical Focus Session
VL: Video Learning Session
8
Wednesday, April 22
European Conference on Interventional Oncology
Wednesday, April 22
08:30-10:00
CF 101 Clinical Focus Session
Early-stage HCC
101.1
101.2
101.3
101.4
101.5
Main Auditorium
Pathology of early HCC
V. Paradis (Clichy/FR)
Imaging of early HCC
C.J. Zech (Basel/CH)
Why and how to biopsy
N.P. Malek (Tübingen/DE)
What to do when on the waiting list for transplantation
P. Majno (Geneva/CH)
Evidence from literature: resection vs. ablation for early HCC
R. Lencioni (Pisa/IT)
10:30-12:00
CF 201 Clinical Focus Session
Intermediate HCC
Main Auditorium
201.1 Critical appraisal of EASL vs. Hong Kong classification
R. Salem (Chicago, IL/US)
201.2 Where does ablation fit in intermediate stage HCC?
P. Chevallier (Nice/FR)
201.3 Drug-eluting beads vs. conventional TACE
T.K. Helmberger (Munich/DE)
201.4 Where does radioembolisation fit in intermediate stage HCC?
B. Sangro (Pamplona/ES)
201.5 Current evidence of systemic therapy in intermediate stage HCC
R. Anty (Nice/FR)
10:30-12:00
TF 202 Technical Focus Session
Top tips
202.1 Radioembolisation: preparation
A. Denys (Lausanne/CH)
202.2 Radioembolisation: treatment
R.J. Lewandowski (Chicago, IL/US)
202.3 DEB TACE
J.G. Caridi (New Orleans, LA/US)
202.4 Lung ablation
G. Carrafiello (Varese/IT)
202.5 Kidney ablation
F. Orsi (Milan/IT)
202.6 Spinal ablation
G. Tsoumakidou (Strasbourg/FR)
202.7 Bone consolidation
F. Deschamps (Villejuif/FR)
Preliminary Programme
Auditorium 2
Wednesday, April 22
ECIO 2015
10:30-12:00
TA-HoW 1 Hands-on Workshop
Image-guided tumour ablation – MSK
9
HoW Room
Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE)
Instructors: A. Gangi (Strasbourg/FR), A.D. Kelekis (Athens/GR), A. Manca (Candiolo/IT)
13:00-14:30
Satellite Symposia
15:00-16:30
IS 401 Interactive Session
Multidisciplinary Tumour Board: HCC
Main Auditorium
Co-ordinator: R. Lencioni (Pisa/IT)
Panellists: R. Anty (Nice/FR), P. Chevallier (Nice/FR), T.K. Helmberger (Munich/DE),
P. Majno (Geneva/CH), W.S. Rilling (Milwaukee, WI/US), R. Salem (Chicago, IL/US)
15:00-16:30
TF 402 Technical Focus Session
Ablation: current status and future horizons
Auditorium 2
402.1 Radiofrequency ablation
B.J. Wood (Bethesda, MD/US)
402.2Electroporation
N. Goldberg (Jerusalem/IL)
402.3Microwaves
P.L. Pereira (Heilbronn/DE)
402.4HIFU
I. Mindjuk (Dachau/DE)
402.5Cryoablation
D.J. Breen (Southampton/UK)
402.6 Immunomodulation with ablation
M. den Brok (Nijmegen/NL)
15:00-16:30
TA-HoW 2 Hands-on Workshop
Image-guided tumour ablation – lung
Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE)
Instructors: S.R. Clasen (Tübingen/DE), A. Gillams (London/UK),
C.T. Sofocleous (New York, NY/US)
e-voting
recommended for EBIR preparation
HoW Room
10
Wednesday, April 22
17:00-18:30
CF 501 Clinical Focus Session
How to follow up patients: clinical and imaging
European Conference on Interventional Oncology
Main Auditorium
501.1 Radioembolisation for CRC
T.K. Helmberger (Munich/DE)
501.2 TACE for HCC
J.-F.H. Geschwind (Baltimore, MD/US)
501.3 Ablation of colorectal liver metastases
B. Guiu (Montpellier/FR)
501.4 Bone ablation
M.R. Callstrom (Rochester, MN/US)
501.5 Ablation of lung metastases
J. Ricke (Magdeburg/DE)
17:00-18:30
CF 502 Clinical Focus Session
Symptomatic cancer treatment
502.1 Systemic pain medication: a practical guide
to be announced
502.2 Evidence-base of radiation therapy for pain
L.M. Kenny (Brisbane/AU)
502.3 Nerve blocks
G. Tsoumakidou (Strasbourg/FR)
502.4 Percutaneous management of pleural effusion
P.E. Bize (Lausanne/CH)
502.5 Percutaneous management of malignant ascites
C. Tapping (Oxford/UK)
18:30-19:00
Satellite Symposia
Preliminary Programme
Auditorium 2
ECIO investigates…
Liver Cancer
Hepatocellular carcinoma, the most common type of liver
cancer, is a growing problem worldwide, due largely to the
increasing prevalence of chronic liver disease. Considerable
progress with respect to detection, diagnosis, surveillance and
treatment has improved outcomes, but HCC is nonetheless the
third leading cause of cancer deaths.
Relatively few patients are eligible for surgery, and systemic
therapy alone is of limited value. Interventional radiology has
greatly broadened treatment options, with ablation potentially curative for early-stage HCC. However, most patients still
present with intermediate or advanced forms of the disease,
meaning palliation plays a predominant role.
Early-stage HCC
Detection and Diagnosis
Early detection and an accurate diagnosis greatly affect a patient’s prognosis. CT and MRI are most commonly used to detect
the disease. Thanks to advances in both imaging and surgical
techniques, small, early-stage HCCs have increasingly been detected, biopsied, resected and subjected to pathological examinations, helping practitioners better understand their histological
features. With imaging techniques enabling more accurate diagnoses, and appreciation of the diagnostic value of contrast washout growing, the need for tissue confirmation has also waned.
Intermediate HCC
Classifications
The Barcelona Clinic Liver Cancer classifications, while widely
endorsed, have also long been criticised for providing insufficient options for practitioners confronting intermediate HCC.
Now some medical centres are considering adopting the new
Hong Kong Liver Cancer classification, and guidelines issued
by the European Association for the Study of the Liver and the
European Organization for Research and Treatment of Cancer
are also receiving much attention. A lecture dedicated to these
two approaches will outline their structure and review how
they impact daily practice for IRs.
Percutaneous Treatment Options
Transarterial chemoembolisation remains the standard treatment for intermediate HCC, but most expect the use of drugeluting beads (DEB-TACE) to further improve results. In the meantime, radioembolisation has become an important therapy option,
but still faces scepticism regarding its competitive efficacy for
HCC beyond the early stage. Treating intermediate HCC with
ablation is an even newer concept. Three presentations will closely examine these approaches, presenting results obtained and
limitations confronted, including from a comparative perspective.
Systemic Therapy
Nonetheless, in daily practice, definitive diagnoses often remain
challenging, particularly with respect to small nodules. Presentations dedicated to pathology, imaging and biopsies will provide delegates with up-to-date information of pathology in early
HCC; outline typical and atypical aspects of the disease on CT
and MRI, as well as limitations of the two imaging techniques;
and will address when it is still necessary to perform a biopsy.
The multi-faceted nature of clinical practice for intermediate
HCC includes systemic therapy with drugs, and several ongoing trials are now evaluating the potential of combining such
therapy with loco-regional treatments. A presentation on systemic therapies will explore the biological background, outline
results achieved, and address at which point such treatments
are best combined with IR procedures.
Curative Treatment Options
Ablation offers a potentially curative option for patients with
small localised HCCs. However, critics note that overall, longterm survival rates are higher after resection, and that recurrence remains an issue, while proponents emphasise that it
involves fewer complications and shorter hospital stays. In other
cases, only liver transplantation is potentially curative, but
patients are either ineligible or confronted with a donor shortage.
Lectures focusing on ablation, resection and transplantation
will outline strategic considerations involved in deciding with
which of these approaches to proceed, and scrutinise the
strength and weaknesses of both the methods and of studies
that seek to compare them.
Colorectal liver metastases
Practitioners have long emphasised the importance of tailored
therapy, but does the concept represent reality or mere hope? A
session jointly held with the European Society for Medical Onco logy will consider this important question in the context of colorectal liver metastases, in addition to reviewing other aspects of
CRCLM, including the current status of systemic therapy, tumour
response following TACE/SIRT, and radioembolisation for palliation.
Other sessions
A Hands-on Workshop will tackle image-guided tumour ablation
in the liver, providing a tangible introduction to the procedure and
the devices it involves, and a Video Learning Session will demonstrate how to perform a wide variety of percutaneous liver
treatments.
12
Thursday, April 23
European Conference on Interventional Oncology
Thursday, April 23
07:45-08:15
Satellite Symposia
08:30-10:00
CF 801 Clinical Focus Session
Lung metastases
Auditorium 2
801.1 How to evaluate lung function before and after surgery, SBRT and ablation?
C. Marquette (Nice/FR)
801.2 Surgery in lung metastases
to be announced
801.3 Is ablation of lung metastases a first line therapy?
A. Gillams (London/UK)
801.4 Imaging follow-up after treatments: surgery, SBRT, ablation
R.D. Suh (Los Angeles, CA/US)
801.5 Evidence from comparative trials for lung metastases
L. Monfardini (Milan/IT)
08:30-10:00
VL 802 Video Learning Session
How I do it: liver
Main Auditorium
802.1 Liver ablation + venous occlusion
T. de Baère (Villejuif/FR)
802.2 Combined cTACE and ablation
L. Crocetti (Pisa/IT)
802.3DEB-TACE
K. Malagari (Athens/GR)
802.4Y-90
J.I. Bilbao (Pamplona/ES)
802.5PVE
P.E. Bize (Lausanne/CH)
10:30-11:30
HL 901 Honorary Lecture
Main Auditorium
Laudation: T. de Baère (Villejuif/FR)
901.1 Beyond the evidence – the true goal of interventional oncology
Y. Arai (Tokyo/JP)
11:30-12:00
PS 902 Paper Session
The best IO papers of 2014
Main Auditorium
10:30-12:00
TA-HoW 3 Hands-on Workshop
Image-guided tumour ablation – liver
HoW Room
Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE)
Instructors: L. Crocetti (Pisa/IT), A.H. Mahnken (Marburg/DE), F. Orsi (Milan/IT)
Preliminary Programme
Thursday, April 23
ECIO 2015
13
13:00-14:30
Satellite Symposia
15:00-16:30
IS 1101 Interactive Session
Multidisciplinary Tumour Board: lung
Auditorium 2 Co-ordinator: A. Gillams (London/UK)
Panellists: M. Bezzi (Rome/IT), L. Monfardini (Milan/IT), S.L. Samuels (Miami, FL/US),
R.D. Suh (Los Angeles, CA/US)
15:00-16:30
JS 1102 Joint Session
Essence of interventional oncology
Joint session with the Japanese Society of Interventional Radiology (JSIR)
Main Auditorium
1102.1 Concept of TACE based on micro-vasculature of HCC
S. Miyayama (Fukui/JP)
1102.2 Intra-arterial infusion therapy – background and challenges
T. Tanaka (Kashihara/JP)
1102.3 Interventional palliative treatment
Y. Inaba (Nagoya/JP)
1102.4 Ablation – combination with other IR techniques
K. Yamakado (Tsu/JP)
1102.5 Clinical trials for evidences of IO
Y. Arai (Tokyo/JP)
15:00-16:30
TA-HoW 4 Hands-on Workshop
Image-guided tumour ablation – kidney
HoW Room
Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE)
Instructors: D.J. Breen (Southampton/UK), C.M. Sommer (Heidelberg/DE)
17:00-18:30
CF 1201 Clinical Focus Session
Ablation: evidence for expanding the boundaries
1201.1Thyroid
J.H. Baek (Seoul/KR)
1201.2Breast
J. Palussière (Bordeaux/FR)
1201.3Adrenal
D.E. Dupuy (Providence, RI/US)
1201.4Lymphnodes
A. Gillams (London/UK)
1201.5Prostate
D.A. Woodrum (Rochester, MN/US)
e-voting
recommended for EBIR preparation
Main Auditorium
14
Thursday, April 23
European Conference on Interventional Oncology
17:00-18:30
CF 1202 Clinical Focus Session
Fundamentals of oncology
1202.1 Conventional chemotherapy
D. Arnold (Freiburg/DE)
1202.2 Targeted therapy: what an interventional oncologist should know
S. Faivre (Lausanne/CH)
1202.3 Phase I, II, III trials: do you really know the differences?
E. François (Nice/FR)
1202.4 How to define response in interventional oncology trials
M. Ronot (Clichy/FR)
1202.5 How endpoints in interventional oncology may differ from medical oncology trials
R. Salem (Chicago, IL/US)
18:30-19:00
Satellite Symposia
Preliminary Programme
Auditorium 2
ECIO investigates…
Lung Cancer
In recent years, ECIO has witnessed an increase in the number of
speakers and sessions addressing pulmonary cancers, both primary
and metastatic. This is clearly a growing area of interest for practitioners of interventional oncology, and as the pool of case reports grows, so the indications for its use are growing ever clearer.
lung metastases, and is achieved by selective embolisation of
the branches of the pulmonary artery. Friday’s Clinical Focus
Session on Intra-arterial therapies: what is the evidence? will
examine the current data for its use in the pulmonary setting
and others.
This year’s congress will feature a number of sessions presenting
this data, and offering valuable advice on patient selection and optimal delivery. These will cover a range of therapeutic applications,
including thermal ablation, mechanical ablation and embolisation.
Multidisciplinary decision-making
Clearly, for both metastatic and primary disease, much more research is needed. Even when clearer indications are eventually
defined, each individual patient will still present with a unique
set of circumstances and determining the optimal therapy (or
therapy combination) is best done in a multidisciplinary setting.
Lung metastases
Currently, the main clinical areas of investigation for imageguided lung therapies are stage I non-small cell lung cancer
(NSCLC) and pulmonary metastases. The latter are a particularly
important area of investigation, as they are among the most
frequently occurring metastases and are found in approximately
50% of autopsy patients. Metastatic lesions, by their very nature,
are often small and multi-nodular, posing challenges for
surgical resection.
Two promising alternatives for pulmonary metastases are ablation and stereotactic body radiation therapy (SBRT), and these
will be examined more closely in Thursday’s Lung metastases
Clinical Focus Session.
SBRT is an extra-cranial radiation therapy which is delivered in
a single or small number of fractions. It is highly precise, and
offers the possibility of controlling for target motion. Despite
its advantages, there remain some limitations regarding the
uncertainty of target definition, dose escalations and inaccurate patient positioning. No clinical trials have yet been
completed, and further investigation is needed.
Likewise, the evidence supporting ablation is far from complete,
but early data indicates that it entails few complications, has
short recovery times and is repeatable. Most importantly of all,
the literature has demonstrated no deterioration of pulmonary
function, which is an important consideration in both the curative and palliative setting. Ensuring clear margins remains a challenge, although using a thermocouple can improve outcomes.
The latest evidence for both therapies, and technical advice of
evaluating lung function and performing adequate follow-up,
will be discussed in this Clinical Focus Session, as well as in the
dedicated How to follow up patients: clinical and imaging session
taking place on Wednesday.
However, ablative techniques are not the only IR procedure
available, and preliminary studies into the palliative use of
intra-arterial techniques have shown promise. This is mainly
used for symptomatic control of bleeding in patients with
To demonstrate and encourage this process, a Multidisciplinary
Tumour Board session will be devoted to examining lung cancer
cases. Practitioners from a range of specialties will be represented, and the session will undoubtedly be informative for all
involved in this field.
Complications
Ablative therapies are not without risk, and it is essential that
practitioners are aware of possible complications, and how
to deal with them. Pneumothorax is the most common complication, but is easily managed with quiet respiration, and
adequate pain control and sedation.
The second most frequent complication is pleural effusion,
which will be explicitly addressed in Wednesday’s Symptomatic
cancer treatment session. Generally, exercising due caution will
prevent this occurring, but if faced with pleural effusion, methods such as observation, thoracentesis and pleural catheter
placement can be employed. Pain is managed with anti-inflammatory agents, narcotics, anti-convulsant drugs, intercostal
nerve block, and hot or cold packs; those wishing to learn
more about this topic should attend Saturday’s Video Learning
Session, How I do it: pain management, for step-by-step
guidance through the use of the PleurX system.
Pseudo-aneurysms and delayed acute haemoptysis are very
rare and cavitation can occur in large ablations, but does not
necessarily indicate infection. A detailed discussion of all lung
ablation complications will be given by noted expert Robert Suh,
in Saturday’s interactive session, Management of complications II.
The full spectrum
The programme for this year’s ECIO will cover the full spectrum of
image-guided therapies for pulmonary cancers, from patient selection to follow-up. Various ablation modalities will be discussed
in a variety of settings, with a Hands-on Workshop on Image-guided tumour ablation – lung giving participants an opportunity to familiarise themselves with a number of devices, and a Video Learning Session guiding attendees through pulmonary cryoablation.
16
Friday, April 24
European Conference on Interventional Oncology
Friday, April 24
07:45-08:15
Satellite Symposia
08:30-10:00
CF 1501 Clinical Focus Session
MSK tumours
Auditorium 2
1501.1 Evidence for ablation in local control
M.R. Callstrom (Rochester, MN/US)
1501.2 Evidence for radiation therapy in local control
B. Jereczek-Fossa (Milan/IT)
1501.3 When does HIFU fit in?
A. Napoli (Rome/IT)
1501.4 Bone consolidation: cementoplasty vs. osteosynthesis
F. Deschamps (Villejuif/FR)
1501.5 When to use embolisation in combination with ablation
A.G. Ryan (Waterford City/IE)
08:30-10:00
JS 1502 Joint Session
Colorectal liver metastases
ECIO invites the European Society for Medical Oncology (ESMO)
Programme to be announced.
10:30-12:00
CF 1601 Clinical Focus Session
Kidney cancer
Main Auditorium
Main Auditorium
1601.1 Renal mass: surveillance protocols, indications for biopsy and thresholds for treatment
to be announced
1601.2 Evidence-based nephron-sparing surgery
C. Anderson (London/UK)
1601.3 Evidence-based ablation vs. resection outcomes
D.J. Breen (Southampton/UK)
1601.4 Systemic and adjuvant treatment in RCC
to be announced
1601.5 Follow-up after ablation: imaging and clinical
D. Gervais (Boston, MA/US)
10:30-12:00
CF 1602 Clinical Focus Session
Intra-arterial therapies: what is the evidence?
1602.1 Liver metastases from melanoma: what is the role of intra-arterial therapies today?
P.L. Pereira (Heilbronn/DE)
1602.2 Neuroendocrine liver metastases: which intra-arterial therapy for which patient?
B. Guiu (Montpellier/FR)
1602.3 Intra-arterial therapy in lung tumours: where do we stand?
J.-P. Pelage (Caen/FR)
1602.4 Cholangiolar carcinoma: the relative role of TACE vs. systemic therapy
W.S. Rilling (Milwaukee, WI/US)
1602.5 Intra-arterial therapy in liver metastases: the 5 best papers of the past year
R.D. Garcia-Mónaco (Buenos Aires/AR)
Auditorium 2
Friday, April 24
ECIO 2015
17
13:00-14:30
Satellite Symposia
15:00-16:30
VL 1801 Video Learning Session
How I do it: lung and kidney
Main Auditorium
1801.1 Lung RFA/MWA
D.E. Dupuy (Providence, RI/US)
1801.2 Lung cryoablation
P.J. Littrup (Detroit, MI/US)
1801.3 Kidney RFA/MWA
F. Cornelis (Bordeaux/FR)
1801.4 Kidney cryoablation
D.J. Breen (Southampton/UK)
1801.5 Percutaneous pancreas IRE
G. Narayanan (Miami, FL/US)
15:00-16:30
CF 1802 Clinical Focus Session
Quality pays: clinical excellence saves money
Auditorium 2
1802.1 Improve quality without added cost: patient pathway in IO
A. Denys (Lausanne/CH)
1802.2 Improve quality without added cost: a structured IO report
A. Gangi (Strasbourg/FR)
1802.3 Cost effectiveness in patient care: what is it, and how to measure it in interventional
oncology?
P. McCrone (London/UK)
1802.4 Disinvestment in medicine, and the need for evidence
L.M. Kenny (Brisbane/AU)
1802.5 The science underpinning interventional oncology: how should we prove the value
of what we do?
R. Lencioni (Pisa/IT)
17:00-18:30
IS 1901 Interactive Session
Management of complications I
1901.1 Liver TACE
S.L. Samuels (Miami, FL/US)
1901.2 Liver ablation
P. Chevallier (Nice/FR)
1901.3Radioembolisation
A.H. Mahnken (Marburg/DE)
1901.4 GI complications
T. Sabharwal (London/UK)
e-voting
recommended for EBIR preparation
Main Auditorium
18
Friday, April 24
European Conference on Interventional Oncology
17:00-18:30
JS 1902 Joint Session
Molecular oncology and translation into the clinic
Joint session with the World Conference on Interventional Oncology (WCIO)
1902.1 Oncogenic pathways and their relevance to interventional oncology
N. Goldberg (Jerusalem/IL)
1902.2 Tumour hypoxia
B.J. Wood (Bethesda, MD/US)
1902.3 Immunomodulation and radioembolisation
J. Ricke (Magdeburg/DE)
1902.4 Tumour metabolism
J.-F.H. Geschwind (Baltimore, MD/US)
1902.5 Image-guided drug activation
R. Duran (Lausanne/CH)
1902.6 DNA repair inhibitor
A. Denys (Lausanne/CH)
18:30-19:00
Satellite Symposia
Preliminary Programme
Auditorium 2
ECIO investigates…
MSK tumours
Interventional radiological treatment of tumours in solid
organs, such as primary or secondary liver tumours or renal
cell carcinoma (RCC) is already well established, or has at
least gained major attention in interdisciplinary discussions.
Moreover, interventional radiology is well established in the
musculoskeletal (MSK) field, mainly in the fields of pain management (e.g. perineural or facet joint infiltration), but a wide
range of tumour-related interventions are also well accepted.
Primary MSK cancers are comparatively rare, but bone metastases, which can derive from any type of primary cancer but
occur frequently in prostate, breast and lung cancer patients,
are quite common. Furthermore, there are a substantial number of benign tumours, such as osteoid osteoma and osteoblastoma, typically occurring in patients aged between 5 and
25 years, or rarer benign tumours, such as desmoid tumours
and haemangiomas, which may present a more aggressive
growth pattern.
Interventional radiology can be performed for curative or
palliative/symptomatic treatment in functionally stable or
unstable, benign or malignant tumours. Furthermore, in many
cases interventional therapy offers local tumour control (e.g. by
thermal destruction), minimisation of fracture risks by stabilisation (e.g. by cementoplasty) together with pain therapy (e.g.
destruction of nociceptors).
In general, all these interventional techniques can be used
in combination with other therapies (e.g. chemotherapy, radiation therapy or surgery), but can also offer the possibility of
symptom relief where other therapies have failed.
Thermal ablation
Thermal ablative techniques, in particular radiofrequency
ablation (RFA), are the method of choice for benign lesions
such as osteoid osteoma and many haemangiomas (mostly
vertebral localisation), but are also applied for destruction in
malignant tumours. The extensive experience in applying RFA
to bone tumours confirms RFA as an easy and safe technique
in many different skeletal localisations with a low risk of complications. The database for other thermal ablative techniques
(microwave ablation, cryoablation, HIFU or laser) is still very
limited and is often only single-centre-based, and more data
is needed to establish the clinical value of each of these
techniques.
Transvascular techniques
Transarterial tumour embolisation in hypervascularised
tumours (e.g. bone metastasis from RCC) is used to make
another therapy easier (e.g. for reducing blood loss during
surgery) or for debulking in large symptomatic tumours where
other therapies have failed or are not amenable.
Augmentation therapies
Musculoskeletal tumours, whether primary or metastatic,
can often compromise the structural integrity of the affected
bone. Whether this occurs due to invasion and displacement
of the healthy tissue, or as a result of therapeutic intervention,
stabilising the bone is important for both patient mobility and
resolution of potential pain.
A number of percutaneous approaches are currently used,
ranging from cementoplasty to the image-guided percutaneous placement of screws or pins (osteosynthesis), or frequently,
a combination of the two. As with thermal ablative procedures,
knowledge of the local anatomy and real-time monitoring is
essential to avoid complications.
This important topic will be addressed in Wednesday’s Top tips
session, where speakers will address both spinal ablation and
bone consolidation, along with other therapies of growing
interest.
Pain therapy/management
Beside thermal ablation of osteoid osteomas, which can be
very painful, most MSK interventional procedures need no
specific pain management and can be performed under local
anaesthesia or mild analgo-sedation. It can be even crucial to
get the immediate feedback from the patient with respect to
pain to avoid serious complications. Nevertheless, interventional therapy of many painful MSK lesions results in immediate pain relief – almost “on the table”.
Risks and complications
Local interventional therapy in MSK structures is straightforward in most cases. Nevertheless, in some cases interdisciplinary assistance is mandatory to get the right access to
a specific lesion (e.g. by mechanical bone drill). The procedure
can also be challenging due to the close anatomical proximity
of crucial structures (e.g. nerve structures) necessitating special
techniques for cooling (e.g. perfusion with a coolant, skin
cooling pads) or dislodgement (e.g. hydrodissection).
MSK programme at ECIO 2015
To ensure comprehensive educational opportunities, the ECIO
2015 programme will be covering MSK tumour therapies in
a range of session formats. A Hands-on Workshop, Clinical
Focus Sessions, Interactive Sessions and even a Video Learning
Session will guide delegates through both the theory and the
practice of a range of treatments. Most importantly of all, the
evidence for their use will be examined alongside radiotherapeutic and surgical options, equipping those practicing MSK
interventions with the skills needed to be clinically involved in
their hospital’s tumour boards.
20
Saturday, April 25
European Conference on Interventional Oncology
Saturday, April 25
08:30-10:00
IS 2101 Interactive Session
Management of complications II
Main Auditorium
2101.1 MSK tumour management
A. Gangi (Strasbourg/FR)
2101.2 Liver ablation
C. Ayuso (Barcelona/ES)
2101.3 Kidney ablation
M. Krokidis (Cambridge/UK)
2101.4 Lung ablation
R.D. Suh (Los Angeles, CA/US)
10:30-12:00
VL 2201 Video Learning Session
How I do it: pain management
2201.1 Splanchnic neurolysis
A.D. Kelekis (Athens/GR)
2201.2 Vertebroplasty and ablation
J. Garnon (Strasbourg/FR)
2201.3PleurX
G. Narayanan (Miami, FL/US)
2201.4 Pelvic osteosynthesis
N. Amoretti (Nice/FR)
2201.5 Hypogastric neurolysis
to be announced
Preliminary Programme
Main Auditorium
EBI R
European Board of Interventional Radiology
Special preparation courses
for the EBIR
The EBIR is a highly valuable qualification in
interventional radiology, based on the
European Curriculum and Syllabus for IR.
Sessions especially suited for EBIR preparation are
highlighted in the ECIO 2015 Scientific Programme
(pages 6-20).
Apply for the 2015 EBIR examinations now online!
For detailed information regarding
examination dates and entry criteria,
please visit our website at www.cirse.org/ebir
Certify your expertise!
European Board of Interventional Radiology
c/o CIRSE
Neutorgasse 9, 1010 Vienna, Austria
[email protected]
www.cirse.org/ebir
C RSE
22
Hands-on Workshops
European Conference on Interventional Oncology
Image-guided tumour ablation
Co-ordinators: M. Bezzi (Rome/IT), P.L. Pereira (Heilbronn/DE)
Image courtesy of Prof. Laura Crocetti
This hands-on workshop will give you the opportunity to
participate in interactive sessions based on case presentations.
Four workshops will each target a specific organ (MSK, lung,
liver and kidney). The cases are presented by leading ablation
experts with many years of experience in an informal inter­
active setting allowing for questions and discussion. A range
of different ablation systems (RFA, cryotherapy and microwave
ablation) and some image guidance technology will be
accessible to the participants during the sessions for ex-vivo
demonstrations.
Learning objectives
– To learn how to handle different energy sources and the
respective equipment for tumour ablation
– To obtain a good understanding of the range of available
ablation techniques and their proper clinical application
– To learn what factors are predictive of success and failure
in order to determine the best indication and optimal
combination of therapies
– To understand the main reported complications of ablation
and the basics of preventing and managing them
– To learn about “tips and tricks” with the use of clinical cases
– To generally learn about the indications of other medical
and surgical treatments
TA-HoW 1
Wednesday, April 22
MSK10:30-12:00
Instructors: A. Gangi (Strasbourg/FR), A.D. Kelekis (Athens/GR),
A. Manca (Candiolo/IT)
TA-HoW 2
Wednesday, April 22
Lung15:00-16:30
Instructors: S.R. Clasen (Tübingen/DE), A. Gillams (London/UK),
C.T. Sofocleous (New York, NY/US)
TA-HoW 3
Thursday, April 23
Liver10:30-12:00
Instructors: L. Crocetti (Pisa/IT), A.H. Mahnken (Marburg/DE),
F. Orsi (Milan/IT)
TA-HoW 4
Thursday, April 23
Kidney15:00-16:30
Instructors: D.J. Breen (Southampton/UK), C.M. Sommer
(Heidelberg/DE)
Location
HoW Room
Please note that participants need to register in advance at an
extra cost of €75.
Preliminary Programme
Registration / CME / Important Addresses
ECIO 2015
Registration
Online registration (secured payment) for ECIO 2015 is available
at www.ecio.org.
Please note that your registration must be submitted and full
payment needs to be received by the respective registration
deadlines. Otherwise the respective next higher fee shall be
due. Furthermore please be advised that incomplete registrations (not containing full name, e-mail and address) cannot be
processed.
Registration Fees
Early – until January 22, 2015 (23:59 CET)
CIRSE Member
Non-Member
Resident / Nurse / Radiographer*
Undergraduate Medical Student** €390
€590
€250
€ 0
Until February 19, 2015 (23:59 CET)
CIRSE Member
Non-Member
Resident / Nurse / Radiographer*
Undergraduate Medical Student** €550
€790
€385
€ 0
After February 19, 2015
CIRSE Member
Non-Member
Resident / Nurse / Radiographer*
Undergraduate Medical Student** €750
€860
€420
€ 0
* To be accompanied by a certificate, signed by the head of department.
** Registration needs to be accompanied by a confirmation of student status at
the time of congress, a one page CV and a copy of a valid photo ID.
Registration fees inclusive of 20% VAT
Under French Fiscal Regulations, VAT (20%) is charged on invoices to all customers
who do NOT have a valid French VAT number. This applies to customers based in
all countries inside and outside the EU. Only if a valid French VAT number is
provided, VAT is not charged.
For all customers who do have a valid French VAT number: Opération bénéficiant
du régime d’auto-liquidation prévu par l’article 283-1 du CGI; TVA due par le client.
Reduced CIRSE Member registration is only available
for members of CIRSE (Cardiovascular and Interventional
Radiological Society of Europe) in good standing.
Method of payment
Registration fees are to be paid in Euros (€) by:
- Bank transfer or Credit Card (Visa or Mastercard)
Subscription to ESIRonline
We are extending year-round ESIRonline access to
non-members: purchase your one-year subscription for
ESIRonline (www.esir.org), for only €30 together with your
registration to ECIO 2015.*
Cancellation of congress registration
CIRSE GmbH offers all pre-registered participants the possibi­li­
ty to take out cancellation insurance with its partner „Europäi­
sche Reiseversicherung“. The insurance can only be booked
during and until finalisation of the online registration process.
The refund of the participant‘s registration fee due to
cancellation of the registration or the change of registration
category is only possible with a valid insurance. CIRSE GmbH
itself will not refund any registration fees. All requests must
be made to „Europäische Reiseversicherung“ directly. Refunds
will be given according to the terms and conditions of the
„Europäische Reiseversicherung“. CIRSE GmbH shall not be
responsible for any refunds of registration fees.
Name changes will be handled as a cancellation and new
registration.
Additional information:
All ECIO 2015 registrants will be able to print out an invoice of
registration using their personal login details at www.ecio.org.
Invoices will be issued by: CIRSE Congress Research Education
GmbH, Neutorgasse 9, 1010 Vienna, Austria
CME Credit Allowance
European Accreditation will be applied for at the EACCME
(European Accreditation Council for Continuing Medical
Education). The EACCME is an institution of the European
Union of Medical Specialists (UEMS), www.uems.net.
Important Addresses
Congress Venue
Nice Acropolis Convention Centre
1 Esplanade Kennedy
06300 Nice, France
Organising Secretariat
CIRSE Central Office
Neutorgasse 9
1010 Vienna, Austria
Phone: +43 1 904 2003
Fax: +43 1 904 2003 30
E-mail: [email protected]
Web: www.ecio.org
E-mail Contacts
For general enquiries about the ECIO 2015 meeting, please
send an e-mail to [email protected].
In case of queries concerning registration for the ECIO 2015
meeting, please send an e-mail to [email protected].
* CIRSE Members in good standing benefit from full access to ESIRonline.
For information about the scientific programme of ECIO 2015,
please send an e-mail to [email protected].
23
24
Accommodation / City Map
European Conference on Interventional Oncology
Accommodation
In cooperation with our travel partner Kuoni DMC, CIRSE has
secured a great number of hotel rooms in Nice for the benefit
of our congress participants. For further information about the
official CIRSE hotels and room bookings, please refer to
www.ecio.org.
If you have any questions, please do not hesitate to contact:
Kuoni Destination Management FR
Contact: Ms Sophie Veyrier
31 avenue Jean Médecin
06000 Nice, France
Phone: +33 1 55 99 98 98
E-mail: [email protected]
List of hotels
1
2
3
4
5
6
7
Hotel
Category
Single Room (€)
Double Room (€)
Travel Time
Public Transport
Taxi
Negresco
Hôtel Beau Rivage
Grand Hotel Aston
NH Hotel
Le Méridien Nice (Classic Room)
Le Méridien Nice (Deluxe City View)
Novotel Acropolis
Ibis Palais des Congrès
5*
4*
4*
4*
4*
4*
4*
3*
274.50
156.50
156.50
161.50
192.50
237.50
147.50
108.00
291.00
168.00
168.00
178.00
210.00
252.00
166.00
119.00
25 min
10 min
5 min
5 min walk
10 min
10 min
4 min walk
9 min walk
All rates are in Euros (€), per room, per night, including breakfast and taxes.
Nice City Map
6
Acropolis
Convention
Centre
3
Tram Station
“Opéra - Vieille Ville“
5
1
Preliminary Programme
2
4
Tram Station
“Acropolis“
7
7 min
5 min
5 min
5 min
5 min
The European Conference on Interventional Oncology is
organised by CIRSE (Cardiovascular and Interventional
Radiological Society of Europe).
The official congress website is: www.ecio.org
To contact the CIRSE Central Office or members of the
committee please write to [email protected].
Print
kompensiert
www.druckmedien.at
GraphX by L O O P . E N T E R P R I S E S media
www.loop-enterprises.com
Preliminary Programme ECIO 2015
In case of any enquiries or comments,
please contact us at [email protected]
© Cardiovascular and Interventional Radiological
Society of Europe / 2014
CIRSE does not accept responsibility for errors or misprints.
Preliminary Programme